medigraphic.com

2012, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (3)

Hypertriglyceridemia and low HDL cholesterol as high impact factors for metabolic syndrome diagnosis in apparently healthy adults

Cifuentes-Goches JC, Gómez-López JD, Hernández-Ancheyta L, Flores-Fuentes SE, Incháustegui-Árias JL, Cañas-Urbina AO

Language: Spanish
References: 21
Page: 301-306
PDF size: 44.34 Kb.


ABSTRACT

Objective: to determine the impact of lipid serum abnormalities and the prevalence of metabolic syndrome (MS) in healthy adults.
Methods: a cross-sectional, prospective and observational study in apparently healthy adults aged 20 to 60 years who had at least three of the following criteria: abdominal obesity (waist circumference › 102 cm in men and › 88 cm in women), triglycerides ≥ 150 mg/dL, HDL cholesterol ‹ 40 mg/dL in men and ‹ 50 mg/dL in women, blood pressure ≥ 130/85 mmHg and fasting glucose ≥ 110 mg/dL).
Results: the prevalence of MS was 20 %, being higher in women (67.7 %) than men (32.3 %). However, no dependence was found with gender (χ2= 2.059, p = 0.151). The age range with a higher prevalence of was 45-49 years. Low HDL cholesterol [HR = 11,059 (3.559, 34.610) p ‹ 0.01], was present in 67.9 % of women and hypertriglyceridemia [HR = 15.53 (4.975, 48.513) p ‹ 0.01] was present in 60.5 % of men.
Conclusions: the results suggested that hypertriglyceridemia and hypoalphalipoproteinemia are high impact factors for MS in adults.


REFERENCES

  1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15(7): 539-553.

  2. Rodríguez-Bernardino A, García-Polavieja P, Reviriego- Fernández J, Serrano-Ríos M. Prevalencia del síndrome metabólico y grado de concordancia en su diagnóstico en pacientes con diabetes mellitus tipo 2 en España. Endocrinol Nutr 2009;57(2):60-70.

  3. Soto V, Vergara E, Neciosup E. Prevalencia y factores de riesgo de síndrome metabólico en población adulta del Departamento de Lambayeque, Perú. Rev Peru Med Exp Salud Publica 2005;22(4):254-261. Disponible en http://redalyc.uaemex.mx/redalyc/pdf/363/36322403.pdf

  4. Florez H, Palacio A, Tamariz L. Síndrome metabólico diabetes y enfermedades cardiovasculares seriamente vinculados. Diabetes Voice 2008; 53(número especial):21-24. Disponible en http://www.idf.org/sites/default/files/attachments/2008_CDM_Florez%20et%20al_ES.pdf

  5. Martínez-Calatrava M, Martínez-Larrad MT, Serrano-Ríos M. Síndrome de resistencia a la insulina y síndrome metabólico: similitudes y diferencias. Síndrome metabólico: concepto, fisiopatología y epidemiología. Cardiovasc Risk Factors 2003;12(2):89-95.

  6. Lerman-Garber I, Aguilar-Salinas CA, Gómez-Pérez FJ, Reza-Albarrán A, Hernández-Jiménez S, Vázquez-Chávez C, Rull J. El síndrome metabólico. Posición de la Sociedad Mexicana de Nutrición y Endocrinología, sobre la definición, fisiopatología y diagnóstico. Características del síndrome metabólico en México. Rev Endocrinol Nutr 2004; 12(3):109-122.

  7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-2752. Disponible en http://circ.ahajournals.org/content/112/17/2735.long

  8. Lombo B, Villalobos C, Tique C, Satizábal C, Franco CA. Prevalencia del síndrome metabólico entre los pacientes que asisten al servicio clínica de hipertensión de la Fundación Santa Fe de Bogotá. Rev Colomb Cardiol 2006;12 (7):472-478.

  9. Zimmet P, Alberti KG, Serrano-Ríos M. A New International Diabetes Federation (IDF) Worldwide Definition of the Metabolic Syndrome: the Rationale and the Results. Rev Esp Cardiol 2005;58(12):1371-1375.

  10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-3421. Disponible en http://circ.ahajournals.org/content/106/25/3143.long

  11. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. [Monografía en internet]. Bélgica: International Diabetes Federation; 2006. Disponible en http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf

  12. Hulley SB, Cummings S. Diseño de la investigación clínica. Barcelona: Doyma; 1993.

  13. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the metabolic syndrome in Latin America and its association with subclinical carotid atherosclerosis: the CARMELA cross sectional study. Cardio vasc Diabetol 2009;8:52. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760519/?tool=pubmed

  14. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011;34(1):216-219. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005489/?tool=pubmed

  15. Rojas R, Aguilar-Salinas C, Jiménez-Corona A, Shamah- Levy T, Rauda J, Ávila-Burgos L. Metabolic syndrome in mexican adults. Results from the national health and nutrition survey 2006. Salud Publica Mex 2010;52(Supl 1):S11-S18. Disponible en http://www.scielosp.org/pdf/spm/v52s1/a04v52s1.pdf

  16. Barquilla A, Polo J, Gómez-Martino JR, Gómez-Barrado J, Martínez-Sánchez JM, Guijarro P, et al. Prevalencia del síndrome metabólico en la población general de la provincia de Cáceres (Estudio SIMCA). SEMERGEN 2009;35 (10):489-497.

  17. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28(7): 1739-1778.

  18. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a mexican nationwide survey. J Lipid Res 2001;42(8): 1298-1307. Disponible en http://www.jlr.org/content/42/8/1298.long

  19. Spiegelman BM, Green H. Control of specific protein biosynthesis during the adipose conversión of 3T3 cells. J Biol Chem 1980;255(18):8811-8818.

  20. Balasubramanyam M, Mohan V. Current concepts of PPARg signaling in diabetes mellitus. Current Science 2000;79 (10):1140-1146.

  21. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration; Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375 (9726);1634-1639. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867029/?tool=pubmed




2020     |     www.medigraphic.com